Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Feb
20
Today In Oncology
Stage II Melanoma Adjuvant Pembrolizumab and Risk of New Skin Cancers
Long-Term Survival Results With Addition of Adjuvant mFOLFOX6 to Hepatectomy in Patients With Liver Metastases From Colorectal Cancer
Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo